Session

Basic research in renal tumours: Looking for the right treatment for the right patient

Poster Session 10

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     T. Klatte, Vienna (AT)
     I. Mincik, Presov (SK)
     G. Stewart, Cambridge (GB)
  • Aims and objectives of this session

    To explore the molecular mechanism of resistance of the different drugs available to treat advanced RCC as well as to select patients sensitive or resistant to the different drugs.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
110
Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma

By: Kitano H.1, Teishima J.1, Yuge R.2, Shinmei S.1, Nagamatsu H.1, Goto K.3, Syoji K.1, Inoue S.1, Hayashi T.1, Sentani K.3, Kitadai Y.2, Yasui W.3, Matsubara A.1

Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Hiroshima University, Dept. of Gastroenterology, Hiroshima, Japan, 3Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan

111
Netrin-1 protein responsible for disease progression in renal cell carcinoma sunitinib resistant tumors

By: Frees S.K., Chavez-Munoz C., Zhou B., Wong A., Raven P., So A.I.

Institutes: Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

112
Acquired resistance to tyrosine kinase inhibitor sunitinib is associated with functional alterations in renal cell carcinoma cell lines

By: Vynnytska-Myronovska B., Schendel D., Unteregger G., Stöckle M., Junker K.

Institutes: Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany

113
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo

By: Imai S., Tei H., Miyake H., Fujisawa M.

Institutes: Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan

114
Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma

By: Stares M.1, Nicol D.2, O’Brien T.3, Challacombe B.3, Rowan A.1, Horswell S.4, Salm M.4, Soultati A.5, Hazell S.6, Chandra A.7, López J.8, Fisher R.9, Chowdhury S.5, Rudman S.5, Gore M.9, Matthews N.10, Fotiadis N.11, Larkin J.9, Turajlic S.1, Swanton C.1

Institutes: 1The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 2The Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 3Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Urology, London, United Kingdom, 4The Francis Crick Institute, Bioinformatics and Biostatistics, London, United Kingdom, 5Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, 6The Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 7Guy’s and St Thomas’ NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, 8Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, 9The Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, 10The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, 11The Royal Marsden Hospital NHS Foundation Trust, Dept. of Interventional Radiology, London, United Kingdom

115
CMG-101: Novel selective mTOR 1/2 inhibitor for renal cell carcinoma

By: Park D.S., Seo J.B., Lee S.R., Hong Y.K., Hong J.Y., Choi K.H.

Institutes: Cha University, Dept. of Urology, Seongnam, South Korea

116
Acceleration of proteinuria without significant impact on renal function and its protection by angiotensin II receptor blocker in rats treated with axitinib

By: Imai S., Miyake H., Fujisawa M.

Institutes: Kobe University Graduate School Of Medicine, Dept. of Urology, Kobe, Japan

117
Predicting clinical response based on ex vivo drug treatment in renal cell carcinoma using kinase activity profiling

By: Oosterwijk-Wakka J.1, Ruijtenbeek R.2, Houkes L.2, Mulders P.1, Oosterwijk E.1

Institutes: 1Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, 2Pamgene International, Research & Development, ‘s Hertogenbosch, The Netherlands

118
Patient-derived avatar mouse models predicts prognosis in advanced renal cell carcinoma

By: Trilla E.1, Regis L.1, Lorente D.1, Servián P.1, Celma A.1, Salvador C.1, Planas J.1, Placer J.1, Suarez C.2, Martinez M.2, Jimenez-Valerio G.2, Detorres I.3, Morales R.2, Jimenez J.4, Vivancos A.4, Nuciforo P.5, Carles J.2, Casanovas O.5, Morote J.1

Institutes: 1Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain, 3Hospital Universitari Vall d’Hebron, Dept. of Pathology, Barcelona, Spain, 4Vall D’Hebron Institute of Oncology, Cancer Genomic Group, Barcelona, Spain, 5Vall D’Hebron Institute of Oncology, Molecular Pathology Group, Barcelona, Spain

119
Interleukin-22 (IL-22), a T-cell secreted cytokine, contributes to renal cell carcinoma (RCC) progression and is associated with poor outcome in RCC patients

By: Rodler S.2, Shangqing S.3, Weidenbusch M.2, Staehler M.5, Seliger B.4, Stief C.G.5, Anders H-J.2, Nuhn P.1

Institutes: 1University Medical Centre Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany, 2Klinikum Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, 3Klinikum Der Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, 4Martin-Luther-University Halle-Wittenberg Institute of Medical Immunology, Institute of Medical Immunology, Halle, Germany, 5Klinikum Universität München, Dept. of Urology, Munich, Germany

120
The Mediator complex subunit MED8 is implicated in the progression of papillary renal cell carcinoma

By: Syring I.1, Klümper N.2, Shaikhibrahim Z.2, Offermann A.2, Braun M.2, Deng M.2, Böhm D.2, Queisser A.2, Von Mässenhausen A.2, Ellinger J.3, Müller S.3, Perner S.4

Institutes: 1University Hospital of Bonn, Dept. of Urology and Pediatric Urology; Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, 2University Hospital of Bonn, Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, 3University Hospital of Bonn, Clinic For Urology and Pediatric Urology, Bonn, Germany, 4University Hospital of Bonn, Department of Prostate Cancer Research, Institute of Pathology; Pathology Network of The University Hospital of Luebeck and Leibniz Research Center Borstel, Bonn, Germany

121
TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target

By: Hayashi T.1, Sentani K.2, Black P.3, Goto K.1, Shinmei S.1, Anami K.2, Oo H.Z.2, Teishima J.1, Yasui W.2, Matsubara A.1

Institutes: 1Hiroshima University, Dept. of Urology, Hiroshima, Japan, 2Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, 3Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

122
Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic reticulum stress synergistically

By: Isono M.1, Sato A.1, Asano T.1, Okubo K.1, Ito K.1, Schulz W.2, Asano T.1

Institutes: 1National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, 2Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

123
Experimental imaging in orthotopic xenograft models of renal cell carcinoma: Comparative evaluation of high-resolution ultrasonography, in-vivo micro-CT and 9.4T MRI

By: Linxweiler J.1, Körbel C.2, Müller A.3, Jung V.1, Jüngel E.4, Siemer S.1, Junker K.1, Menger M.D.2, Saar M.1

Institutes: 1Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany, 2Saarland University Medical Center, Dept. of Clinical-Experimental Surgery, Homburg/Saar, Germany, 3Saarland University Medical Center, Dept. of Diagnostic and Interventional Radiology, Homburg/Saar, Germany, 4Frankfurt University Medical Center, Dept. of Urology, Frankfurt am Main, Germany